RegenXBio (RGNX) Receives a Buy from Morgan Stanley


In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on RegenXBio (RGNX), with a price target of $59.00. The company’s shares closed last Monday at $38.88.

According to TipRanks.com, Harrison is a 4-star analyst with an average return of 4.3% and a 53.5% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Global Blood Therapeutics, and Fulcrum Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for RegenXBio with a $96.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $73.81 and a one-year low of $30.38. Currently, RegenXBio has an average volume of 545.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts